Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

Phase 4 Unknown 150 enrolled Tan Tock Seng Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.

Timeline

Start: 2019-04-01
Primary completion: 2023-05-10
Completion: 2023-05-10

Outcome

Missed primary endpoint

paper RHI did not differ significantly between groups (primary endpoint). PMID 42396722 ↗

Publications

Chee YJ, Acharyya S, Liew H, Seow CJ, Goh LL, Boehm BO, Dalan R. First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial. Diabetes Obes Metab. 2026 Jul 3. doi: 10.1111/dom.71056. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	5 mg	—
Subject	Dapagliflozin	Small molecule	10 mg	—
Comparator	Metformin	Small molecule	500 mg	Oral